Zoetis, the world's largest manufacturer of medicines and vaccinations for pets and livestock, announced on June 27 that it had received European Commission approval for the Suvaxyn PRRS MLV variation group.

Suvaxyn PRRS MLV is an innovative vaccine that contains a modified strain of live European pig reproductive and respiratory syndrome virus (PRRS). This provides earlier protection of pigs, sows and piglets from diseases, and also increases the duration of their immunity.

As a result of the use of the vaccine, the period of occurrence of immunity in pigs, piglets and sows is reduced from 28 to 21 days, and the duration of immunity in pigs is increased from 16 to 26 weeks.

The immunity of pigs is established 21 days after vaccination and lasts for 26 weeks in the fattening of pigs, piglets and sows.

“We are very excited about the new variation group for Suvaxyn PRRS MLV, which allows veterinarians and pig farmers to effectively protect young piglets and overcome potential interference with maternal immunity.

This is the only PRRS vaccine approved in Europe for administration from the first day of life, which induces effective immunity against PRRS only 21 days after administration. This provides a unique opportunity to get protected piglets at a time of high risk of weaning, ”said Dr. Monika Balash, Director of Global Research and Development in Veterinary Biology at Zoetis.